• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国卫生研究院文献>Frontiers in Pharmacology >Scutellarin Enhances Antitumor Effects and Attenuates the Toxicity of Bleomycin in H22 Ascites Tumor-Bearing Mice
【2h】

Scutellarin Enhances Antitumor Effects and Attenuates the Toxicity of Bleomycin in H22 Ascites Tumor-Bearing Mice

机译：黄cut苷可增强H22腹水荷瘤小鼠的抗肿瘤作用并降低博来霉素的毒性。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Bleomycin (BLM) is a broad spectrum anti-tumor drug and inducing pulmonary fibrosis. As an anti-tumor drug without immunosuppression, it is urgent to find a drug that reduces the side effects of BLM. Scutellarin (SCU), a flavone extracted from Erigeron breviscapus (Vant.) Hand-Mazz, has anti-inflammatory activity and ability to inhibit tumor cell growth, migration, and invasion. However, the combined role of SCU and BLM treatment in tumor is unclear. This study aimed to investigate the possible effect and related mechanisms of BLM combined with SCU in the treatment of tumor through in vivo and in vitro experiments. In vivo experiments showed that BLM combined with SCU in the treatment of mice bearing H22 ascites tumor prolonged the survival time, alleviated BLM-induced pulmonary fibrosis, reduced the production of TNF-α; IL-6, and the levels of MDA and MPO. BLM combined with SCU increased the apoptotic rate of H22 ascites cells and the levels of cleaved-caspases-3 and -8. Furthermore, BLM combined with SCU increased the protein expression of p53 and gene expression of miR-29b, and decreased the expression of TGF-β1. In vitro experiment results showed that BLM combined with SCU inhibited the viability of H22 cells and MRC-5 cells, promoted H22 cell apoptosis, up-regulated the protein expression of p53 and down-regulated the protein expression of α-SMA and collagen-I in MRC-5 cells. These experimental results suggested that SCU could enhance the anti-tumor effect of BLM and reduce BLM-induced pulmonary fibrosis, indicating SCU as a potential adjuvant for BLM in the future.
机译：博来霉素（BLM）是一种广谱抗肿瘤药物，可诱导肺纤维化。作为一种没有免疫抑制作用的抗肿瘤药物，迫切需要找到一种能够减轻BLM副作用的药物。黄cut苷（SCU）是从灯盏花（Erigeron breviscapus）（Vant。）Hand-Mazz中提取的黄酮，具有抗炎活性，并具有抑制肿瘤细胞生长，迁移和侵袭的能力。但是，尚不清楚SCU和BLM治疗肿瘤的联合作用。本研究旨在通过体内外实验研究BLM联合SCU治疗肿瘤的可能作用及相关机制。体内实验表明，BLM联合SCU治疗荷H22腹水瘤小鼠可延长生存期，减轻BLM诱导的肺纤维化，降低TNF-α的产生； IL-6，以及MDA和MPO的水平。 BLM与SCU联合可提高H22腹水细胞的凋亡率以及裂解的胱天蛋白酶3和-8的水平。此外，BLM与SCU联合可增加p53的蛋白表达和miR-29b的基因表达，并降低TGF-β1的表达。体外实验结果表明，BLM联合SCU抑制H22细胞和MRC-5细胞的活力，促进H22细胞凋亡，上调p53蛋白表达，下调α-SMA和胶原蛋白I的表达。在MRC-5细胞中这些实验结果表明，SCU可以增强BLM的抗肿瘤作用，并减少BLM诱导的肺纤维化，表明SCU可能成为BLM的潜在佐剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号